Kornitzer Capital Management Inc. KS Acquires 600 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Kornitzer Capital Management Inc. KS raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 119,262 shares of the medical research company’s stock after acquiring an additional 600 shares during the quarter. Kornitzer Capital Management Inc. KS owned approximately 0.07% of IQVIA worth $27,595,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in IQV. AdvisorNet Financial Inc grew its stake in shares of IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares in the last quarter. BKM Wealth Management LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $32,000. Activest Wealth Management bought a new position in shares of IQVIA during the 4th quarter worth approximately $35,000. Live Oak Investment Partners bought a new position in shares of IQVIA during the 4th quarter worth approximately $41,000. Finally, CVA Family Office LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $43,000. 89.62% of the stock is owned by institutional investors.

Insider Transactions at IQVIA

In other news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Up 0.4 %

IQV opened at $228.09 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. The company has a market capitalization of $41.40 billion, a P/E ratio of 31.29, a P/E/G ratio of 2.21 and a beta of 1.50. The stock has a fifty day moving average of $244.82 and a 200-day moving average of $221.87.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter last year, the firm earned $2.54 earnings per share. The company’s revenue was up 3.5% on a year-over-year basis. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on IQV shares. UBS Group raised their price target on shares of IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. SVB Leerink began coverage on IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective for the company. BTIG Research began coverage on IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective for the company. Guggenheim downgraded IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Finally, Truist Financial increased their price objective on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.